Citadel Advisors
SLNO

Citadel Advisors’s Soleno Therapeutics SLNO Stock Holding History

Citadel Advisors’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.88M Sell
56,100
-49,700
-47% -$1.95M ﹤0.01% 6195
2025
Q4 		$4.9M Buy
105,800
+16,900
+19% +$927K ﹤0.01% 4319
2025
Q3 		$6.01M Buy
88,900
+69,100
+349% +$5.12M ﹤0.01% 4023
2025
Q2 		$1.66M Sell
19,800
-422,100
-96% -$31.6M ﹤0.01% 6065
2025
Q1 		$31.6M Buy
441,900
+302,300
+217% +$14.7M 0.01% 1541
2024
Q4 		$6.28M Buy
139,600
+126,700
+982% +$6.56M ﹤0.01% 3607
2024
Q3 		$651K Buy
12,900
+6,600
+105% +$316K ﹤0.01% 7702
2024
Q2 		$257K Sell
6,300
-28,100
-82% -$1.19M ﹤0.01% 9435
2024
Q1 		$1.47M Buy
34,400
+22,300
+184% +$1.01M ﹤0.01% 6128
2023
Q4 		$487K Buy
+12,100
New +$344K ﹤0.01% 8166
2022
Q3 		– Sell
-7,340
Closed -$20K – 13527
2022
Q2 		$20K Sell
7,340
-4,987
-40% -$13.8K ﹤0.01% 12409
2022
Q1 		$41K Sell
12,327
-480
-4% -$2.48K ﹤0.01% 12921
2021
Q4 		$79K Buy
12,807
+6,927
+118% +$72.7K ﹤0.01% 12955
2021
Q3 		$82K Buy
5,880
+2,607
+80% +$36.4K ﹤0.01% 13055
2021
Q2 		$56K Buy
3,273
+1,733
+113% +$29.3K ﹤0.01% 13288
2021
Q1 		$29K Sell
1,540
-1,753
-53% -$56.5K ﹤0.01% 13035
2020
Q4 		$95K Buy
3,293
+1,786
+119% +$51.5K ﹤0.01% 10251
2020
Q3 		$57K Sell
1,507
-2,073
-58% -$60.6K ﹤0.01% 9550
2020
Q2 		$119K Buy
+3,580
New +$155K ﹤0.01% 8893

Other funds holding SLNO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return

Citadel Advisors's SLNO Position: Q1 2026 in Review

Citadel Advisors increased its Soleno Therapeutics (SLNO) stake by 25% in Q1 2026, buying an estimated $3.05M and bringing the position to 386,545 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2881.

Citadel Advisors first reported a position in SLNO in Q2 2015 and has held it in 23 quarters since. The position peaked at $126M in Q2 2025. 225 funds tracked by Wall St. Rank hold SLNO as of Q1 2026.

  • Citadel Advisors held 386,545 shares of Soleno Therapeutics worth $12.9M as of Q1 2026.
  • Citadel Advisors bought 77,715 Soleno Therapeutics shares in Q1 2026, an estimated $3.05M.
  • Soleno Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #2881 holding.
  • Citadel Advisors first reported a position in Soleno Therapeutics in Q2 2015 and has held it in 23 quarters since.
  • Citadel Advisors's Soleno Therapeutics position peaked at $126M in Q2 2025.
  • 225 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.